Scholarlink

<p>Current treatment strategies for glioblastoma, including resection followed by concurrent chemotherapy/radiotherapy are not curative. Angiogenesis and hypoxia are two major factors responsible for GBM growth and resistance to existing therapies, leading to poor clinical outcomes. The transcription factor NF‐κB induces tumour progression by activating genes associated with cell proliferation and angiogenesis. It is expressed constitutively in gliomas and is known to regulate the expression of HIF‐1α and VEGF in GBM. As a result, NF‐κB can be a potent target that can inhibit tumour growth/invasiveness by reducing hypoxia and angiogenesis, as well as preventing macrophage and microglia infiltration and generating inflammatory cytokines that cause gliomagenesis. AAV vectors are the typical transducing agents for gene therapy because they can infect a broad range of dividing and non-dividing cell types. AAVs have emerged as one of the most widely used methods for delivering genes into the central nervous system because of their broad range of infectivity, ability to induce long-term transgenic expression, and lack of toxicity. The present study aims to inhibit NF‐κB activity by blocking its nuclear translocation via overexpression of IκBα utilising recombinant adeno-associated virus‐5 plasmid as a gene therapy vector.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Therapeutic Potential of NF-κB Inhibition in Glioblastoma: Gene Therapy Approach with rAAV-5 Mediated IκBαM Overexpression

  • 期刊论文

  • 发表日期：

    2025年3月26日

查看全文
  • Ceera Manikandan,
  • Amit Kumar Jaiswal

摘要

Current treatment strategies for glioblastoma, including resection followed by concurrent chemotherapy/radiotherapy are not curative. Angiogenesis and hypoxia are two major factors responsible for GBM growth and resistance to existing therapies, leading to poor clinical outcomes. The transcription factor NF‐κB induces tumour progression by activating genes associated with cell proliferation and angiogenesis. It is expressed constitutively in gliomas and is known to regulate the expression of HIF‐1α and VEGF in GBM. As a result, NF‐κB can be a potent target that can inhibit tumour growth/invasiveness by reducing hypoxia and angiogenesis, as well as preventing macrophage and microglia infiltration and generating inflammatory cytokines that cause gliomagenesis. AAV vectors are the typical transducing agents for gene therapy because they can infect a broad range of dividing and non-dividing cell types. AAVs have emerged as one of the most widely used methods for delivering genes into the central nervous system because of their broad range of infectivity, ability to induce long-term transgenic expression, and lack of toxicity. The present study aims to inhibit NF‐κB activity by blocking its nuclear translocation via overexpression of IκBα utilising recombinant adeno-associated virus‐5 plasmid as a gene therapy vector.